0001209191-19-049534.txt : 20190913 0001209191-19-049534.hdr.sgml : 20190913 20190913185256 ACCESSION NUMBER: 0001209191-19-049534 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190912 FILED AS OF DATE: 20190913 DATE AS OF CHANGE: 20190913 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shannon James Samuel CENTRAL INDEX KEY: 0001485417 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 191093459 MAIL ADDRESS: STREET 1: 28903 NORTH AVENUE PAINE CITY: VALENCIA STATE: CA ZIP: 91355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-12 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001485417 Shannon James Samuel C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 1 0 0 0 Ordinary Shares 2019-09-12 4 M 0 15500 12.19 A 15500 D Ordinary Shares 2019-09-12 4 S 0 15500 26.5891 D 0 D Ordinary Shares 2019-09-13 4 M 0 9500 12.19 A 9500 D Ordinary Shares 2019-09-13 4 S 0 9500 26.19 D 0 D Ordinary Shares 19272 I By Trust Stock Option (Right to Buy) 12.19 2019-09-12 4 M 0 15500 0.00 D 2027-08-01 Ordinary shares 15500 36732 D Stock Option (Right to Buy) 12.19 2019-09-13 4 M 0 9500 0.00 D 2027-08-01 Ordinary shares 9500 27232 D The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.49 to $26.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.18 to $26.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The 52,232 shares originally subject to the option vest in 36 equal monthly installments from the date of grant (August 2, 2017). /s/ Miles W. McHugh, Attorney-in-Fact 2019-09-13